Category: Markets
Published: 2026-06-22T14:14:39.000Z
Insulet Corporation released new clinical results for its Omnipod 6 and a fully closed-loop (FCL) system for type 2 diabetes, showing significant improvements. The Omnipod 6 improved time in tight range for both type 1 and type 2 patients and delivered up to 50% more automated insulin. The FCL system for type 2 diabetes achieved a 12% improvement in time in range and reduced daily insulin, with a commercial launch targeted for 2028.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.